Spatial CRISPR Screening for Drug Discovery

Researchers are integrating spatial analysis into CRISPR screening to improve the identification of therapeutic targets and the understanding of disease mechanisms. This approach, described in reporting from Drug Discovery News on April 11, 2026, utilizes imaging-integrated sorting to reveal spatial phenotypes, allowing scientists to uncover targets in various diseases by observing where specific biological changes occur within a tissue or cellular environment.

Traditional CRISPR screening often provides data on a bulk level, but the addition of a spatial lens allows for a more precise view of how genetic perturbations affect cells in their native architecture. This evolution in functional genomics is designed to bridge the gap between identifying a genetic driver and understanding its physical role within a complex biological system.

Spatially Resolved Multiomic Analysis in 3D Models

One specific advancement in this field is a technology called SPACE, which stands for spatially resolved multiomic analysis for high-throughput CRISPR screening in 3D models. According to a study published on bioRxiv on September 14, 2025, this method provides a scalable and cost-effective approach to high-throughput spatial perturbation studies.

To demonstrate the utility of SPACE, researchers performed the analysis across hundreds of spheroids. This application led to the discovery of novel biology specifically related to interactions between cancer-associated fibroblasts (CAFs) and tumors. The researchers, which included contributors from Merck & Co. And Bruker Spatial Biology, indicated that the technology has broad applications in drug discovery and translational research.

Impact on Drug Discovery and Target Identification

The broader application of CRISPR-Cas9 screening technology is redefining how therapeutic targets are identified. As detailed in a June 2, 2025, article in the Journal of Pharmaceutical Analysis, these screenings provide a precise and scalable platform for functional genomics, which streamlines the process of drug discovery.

Beyond general target identification, these tools are being used to address specific clinical challenges, such as medication failure. Research published on April 17, 2025, via ScienceDirect, highlights the use of a pooled lentiviral CRISPR/Cas9 screening approach to identify genes responsible for drug resistance.

By combining these pooled screening methods with spatial transcriptomics, researchers can better understand the limitations of current treatments and identify new genetic vulnerabilities that can be targeted by future drugs.

Translational Applications

The transition toward spatial CRISPR screening represents a shift toward more biologically relevant models. The use of 3D models, such as the spheroids used in the SPACE analysis, more closely mimics the environment of human organs and tumors than traditional 2D cell cultures.

This capability allows researchers to observe how a gene knockout or activation affects not only the target cell but also its neighboring cells and the surrounding extracellular matrix. This level of detail is critical for understanding complex diseases where cell-to-cell communication, such as the CAF-tumor interactions, plays a primary role in disease progression or treatment resistance.